Chase Investment Counsel Corp Invests $2.04 Million in Halozyme Therapeutics, Inc. $HALO

Chase Investment Counsel Corp purchased a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 26,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,035,000.

A number of other hedge funds have also recently added to or reduced their stakes in HALO. Mizuho Markets Americas LLC increased its holdings in shares of Halozyme Therapeutics by 270.8% in the fourth quarter. Mizuho Markets Americas LLC now owns 1,268,673 shares of the biopharmaceutical company’s stock valued at $85,382,000 after purchasing an additional 926,526 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in Halozyme Therapeutics by 19,326.4% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 85,476 shares of the biopharmaceutical company’s stock valued at $5,753,000 after buying an additional 85,036 shares during the last quarter. Hussman Strategic Advisors Inc. boosted its position in Halozyme Therapeutics by 66.7% in the 4th quarter. Hussman Strategic Advisors Inc. now owns 52,500 shares of the biopharmaceutical company’s stock valued at $3,533,000 after buying an additional 21,000 shares during the last quarter. William Blair Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics in the 4th quarter valued at $124,031,000. Finally, Asset Management One Co. Ltd. raised its position in shares of Halozyme Therapeutics by 1,358.0% during the fourth quarter. Asset Management One Co. Ltd. now owns 24,844 shares of the biopharmaceutical company’s stock worth $1,713,000 after acquiring an additional 23,140 shares during the last quarter. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $98.66 on Monday. The stock has a 50 day simple moving average of $79.66 and a 200 day simple moving average of $72.56. Halozyme Therapeutics, Inc. has a 52-week low of $61.22 and a 52-week high of $104.78. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. The firm has a market capitalization of $11.20 billion, a PE ratio of 29.45, a P/E/G ratio of 0.40 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, topping the consensus estimate of $1.79 by $0.49. The firm had revenue of $481.00 million for the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. The business’s quarterly revenue was up 47.7% on a year-over-year basis. During the same period last year, the company posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Sell-side analysts predict that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on HALO. Citizens Jmp lifted their price objective on Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a research report on Friday, August 7th. Wells Fargo & Company lifted their price target on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. Benchmark reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. Finally, TD Cowen upped their target price on shares of Halozyme Therapeutics from $96.00 to $105.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Nine research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $91.20.

Insider Buying and Selling

In other Halozyme Therapeutics news, CEO Helen Torley sold 1,923 shares of the stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $79.77, for a total transaction of $153,397.71. Following the completion of the transaction, the chief executive officer owned 767,780 shares in the company, valued at approximately $61,245,810.60. This represents a 0.25% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of Halozyme Therapeutics stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the sale, the director directly owned 40,418 shares in the company, valued at $4,154,970.40. This represents a 3.87% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 44,103 shares of company stock worth $3,142,896 over the last ninety days. Company insiders own 2.50% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.